Skip to Content


Lisa Gillespie, quoting Rachel Sachs (Academic Fellow Alumna)
WFPL
October 20, 2018

Read the full article

From the article:

Rachel Sachs, an associate professor of law and a drug regulation expert at Washington University, said that the proposal is very narrow and doesn’t do anything for transparency for many drugs.

“We’re already talking about a subset of products. Older products, even if they’re expensive products like insulin, typically they aren’t advertised in this way,” Sachs said. “So for those products, there won’t be even the kind of transparency that could be the benefit of this proposal.”

Read more here!

Read the full article

Tags

fda   pharmaceuticals   rachel sachs   regulation